Published online before print June 12, 2009

This Article Full Text Full Text (PDF) All Versions of this Article: jmoldx.2009.080121v1 11/4/319    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ahn, J.-Y. Articles by Arber, D. A. Search for Related Content PubMed PubMed Citation Articles by Ahn, J.-Y. Articles by Arber, D. A.

Journal of Molecular Diagnostics 2009, Vol. 11, No. 4
Copyright © 2009 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2009.080121

A Comparison of Two Methods for Screening CEBPA Mutations in Patients with Acute Myeloid Leukemia

Jeung-Yeal Ahn^*, Katie Seo^*, Olga Weinberg^*, Scott D. Boyd^* and Daniel A. Arber^*

From the Department of Pathology, * Stanford University School of Medicine, Stanford, California; and the Department of Laboratory Medicine, Gachon University Gil Hospital, Incheon, Korea

The goal of the study was to compare the performance of a fluorescence-based multiplex PCR fragment analysis to a direct sequencing method for detecting CEBPA mutations in patients with acute myeloid leukemia. Thirty-three samples were selected from a larger study of 107 cases of acute myeloid leukemia by screening for CEBPA mutations by sequence analysis. Of ten identified mutations, six (insertions and deletions) were detected by both sequencing and fragment methods. The fragment analysis method did not detect the remaining four base substitutions because the method cannot detect changes that result in identically sized products. The multiplex PCR fragment length analysis method therefore failed to detect substitution mutations accounting for 40% of total CEBPA mutations in our patient set. Our results indicate that fragment length analysis should not be used in isolation, and that direct sequencing is required to evaluate CEBPA gene mutational status in acute myeloid leukemia. A combination of the two assays may offer some advantages, chiefly in permitting more sensitive detection by fragment length analysis of insertions and deletions.